Konference: 2006 48th ASH Annual Meeting - účast ČR
Kategorie:
Myelodysplastický syndrom
Téma: Simultaneous session: Myelodysplastic Syndromes: Treatment
Číslo abstraktu: 519
Autoři: MD Theo M. de Witte; Ronald Brand; Anja van Biezen; Ghulam J. Mufti, DM, FRCP, FRCPath; Tapani Ruutu; Prof. Dr. med. Jürgen Finke; Peter von dem Borne; MUDr. Antonín Vítek; MD Michel Delforge, PhD; MD Emilio Paolo Alessandrino; Nicholas Harhalakis; Prof. MD Nigel H. Russell; Enric Carreras; Leo F. Verdonck; W. Dietger
Early alloSCT of pts with MDS before transformation usually results
in a 50% EFS, but the nonrelapse mortality (NRM) has precluded a
general application of alloSCT for patients with RA. Introduction
of RIC has allowed the application of alloSCT to more advanced
ages. This study evaluated the impact of recipient age, transplant
year, interval between diagnosis and SCT (Dx-SCT), cytogenetic
characteristics, T-cell depletion (TCD), type of donor, and the
intensity of the conditioning regimen on the outcome of alloSCT.
The study population consisted of 374 pts, 244 of whom have
received a transplant from an HLA-id. sibling. None of the pts had
progressed to advanced stages of MDS. 83 Pts received TCD grafts
and 102 pts received SCT after RIC. 58 Pts were <20 yrs, 52
between 20-30, 66 between 30-40, 95 from 40-50 and 103 pts >50
yrs. 86 Pts received SCT before 1996, 125 in 1997-2001, and 163 pts
more recently. 184 Pts have been transplanted with a Dx-SCT of
<12 months, and 190 >12 months. Cytogenetic data were
available for 197 pts, 85 of whom had cytogenetic abnormalities.
The overall 5-year survival was 50% (SE: 3%). Relapse occurred in
44% pts resulting in a 5-year relapse risk of 21% (SE: 3%). NRM was
the cause of failure in 120 pts resulting in a 5-year NRM of 41%
(SE: 3%). The survival after SCT with matched related and unrelated
donors was 54% and 48% resp. Young age was associated with better
survival in the univariate model (p=0.04). An association exists
between various factors such as between age and regimen type,
transplantation year, or donor type. Therefore the outcome of the
multivariable analyses was based on Cox models with age, transplant
year, type of donor, Dx-SCT, stem cell source, and regimen type as
main factors. Variables with a significant impact on survival were
transplant year with an improved survival in more recently
performed SCT (HR=0.95/year; p=0.05), TCD (HR=1.5; p=0.03) and
Dx-SCT >12 months (HR=1.4; p=0.05) while higher age (HR=1.1/10
years; p=0.08) and RIC (HR=1.0; p=1.0) did not influence outcome
significantly. The HR of RIC for relapse-free survival was 1.2;
p=0.5. The fully adjusted estimate for relapse after RIC was HR=4.1
(p=0.002). The NRM was lower after RIC: HR 0.7 (P=0.22), but this
difference was not significant. The donor type and the source of
stem cells did not influence significantly any of the outcome
variables. This data show that alloSCT results in excellent outcome
nowadays, even at older age and using matched unrelated donors. The
relatively high relapse rate observed after RIC warrants
prospective studies.
Datum přednesení příspěvku: 11. 12. 2006